![](/images/graphics-bg.png)
Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
المؤلفون المشاركون
Suarez-De-Figueroa, Marta
Araiz, Javier
García-Arumí, José
Cervera, Enrique
Manzanas, Lucía
Fonollosa, Alex
Donate, Juan
Crespí, Jaume
Gallego, Roberto
Gómez-Ulla, Francisco
Navea-Tejerina, Amparo
Arias, L.
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-10-14
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objectives.
To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO).
Design, Setting, and Patients.
Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals.
Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016.
Intervention.
Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing.
Main Outcomes.
Mean change in BCVA after 12 months.
Results.
24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days.
Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001.
Twelve (50.0%) patients gained ≥15 ETDRS letters.
Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P<0.0001.
At Month 12, 8.3% patients had MO.
The mean (SD) number of injections: 8.3 (3.0).
No treatment-related AEs were reported.
Five (20.8%) patients experienced ocular AEs.
Two nonocular serious AEs were reported.
Conclusions.
An aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
García-Arumí, José& Gómez-Ulla, Francisco& Navea-Tejerina, Amparo& Cervera, Enrique& Fonollosa, Alex& Arias, L.…[et al.]. 2018. Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial. Journal of Ophthalmology،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196973
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
García-Arumí, José…[et al.]. Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial. Journal of Ophthalmology No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1196973
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
García-Arumí, José& Gómez-Ulla, Francisco& Navea-Tejerina, Amparo& Cervera, Enrique& Fonollosa, Alex& Arias, L.…[et al.]. Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial. Journal of Ophthalmology. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1196973
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1196973
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)